The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.
Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. ⋯ Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the 177Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11 .).
-
Letter Case Reports
Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.
-
Historical Article
Rethinking the Ban - The U.S. Blood Supply and Men Who Have Sex with Men.